文献速递其他结缔组织病自身炎症与 IgG4 相关病

风湿免疫科医生在肿瘤免疫治疗相关不良事件管理中的角色演变

The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy.
PubMed 文献 · Ann Rheum Dis · 2017-09-19

本文为综述,讨论癌症免疫检查点抑制剂引发的免疫相关不良事件(irAEs)具有自身免疫和/或自身炎症性质,给患者管理带来挑战。作者认为风湿免疫科医生因熟悉多器官自身免疫病及传统与生物免疫治疗经验,应成为该领域的核心参与者,并亟需接受相关教育。

要点

  • irAEs 具有自身免疫和/或自身炎症性质,管理需兼顾毒性控制与抗肿瘤治疗继续。
  • 风湿免疫科医生应作为核心参与者介入 irAEs 管理,而非仅处理风湿性 irAEs。
  • 风湿免疫科医生亟需该领域教育,以胜任临床照护与机制研究。

核心结论

  • 风湿免疫科医生有必要也有机会成为 irAEs 管理领域的核心力量。
  • 风湿免疫科医生亟需接受 irAEs 相关教育,以参与患者照护和机制研究。

研究设计与样本

  • 本文为综述,围绕癌症免疫检查点抑制剂所致 irAEs 的管理与风湿免疫科医生角色进行论述。

主要发现

  • 免疫检查点抑制剂治疗引发了一类看似源于自身免疫和/或自身炎症的新型毒性,即 irAEs。
  • irAEs 在如何优化管理这些严重毒性同时允许有效抗肿瘤治疗继续方面,给患者照护带来相当大的挑战。
  • 风湿免疫科医生对多器官自身免疫病的熟悉及在传统与生物免疫治疗方面的专长,是参与该领域的理由。

临床怎么用

  • 风湿免疫科医生除管理风湿性 irAEs 外,应作为核心参与者加入 irAEs 多学科管理。
  • 应开展 irAEs 相关教育,使风湿免疫科医生胜任此类患者照护及并发症机制研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The rapid introduction of immunotherapies for cancer-targeting immunological checkpoints has led to a new class of toxicities that appear to be of autoimmune and or autoinflammatory origin. These disorders are now referred to as immune-related adverse events (irAEs) and pose considerable challenges to patient care in terms of how to optimally manage these formidable toxicities while allowing effective antitumoural therapy to continue. While rheumatologists will naturally be called on to manage those irAEs of rheumatic origin, we believe there is a need and an opportunity for rheumatologists to participate as central figures in this evolving field, in large part because of our familiarity with multiorgan autoimmune disease and our expertise in crafting and utilising both traditional and biological immune-based therapies. Rheumatologists urgently need education in this evolving field to be best positioned as contributors to care of such patients and investigators of the underlying mechanisms of these complications.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Calabrese L, Mariette X. The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy. Ann Rheum Dis. 2017. PMID: 28928270. doi:10.1136/annrheumdis-2017-212061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。